Case Discussion: Integrating PSMA PET for Focal Boost Optimization
Panelists discuss how PSMA PET imaging identified a region of high tracer uptake, guiding medical professionals to implement a focal radiation boost. This approach improved treatment precision and targeting of aggressive areas, highlighting the potential for personalized, effective therapies.
EP: 1.The Evolving Role of PSMA PET in Prostate Cancer Imaging and Management
EP: 2.PSMA PET Imaging Agents: Image Quality and Diagnostic Performance
EP: 3.Selecting the Optimal PSMA PET Imaging Agent: Clinical Considerations and Data-Driven Decisions
EP: 4.Imaging Quality in Prostate Cancer: Impact on Treatment Decision-Making
EP: 5.PSMA PET Imaging in Prostate Cancer Staging: Guiding Initial Diagnosis and Treatment Decisions
EP: 6.PSMA PET Imaging in Biochemical Recurrence: Clinical Approaches and Data-Driven Decisions
EP: 7.Role of PSMA PET Imaging in Guiding Surgical Treatment Decisions in Prostate Cancer
EP: 8.Leveraging PSMA PET Imaging in Posttreatment Response Assessment: Evolving Practices and Data Insights
EP: 9.Utilizing PSMA PET Imaging in Metastatic Prostate Cancer to Guide Treatment Strategies
EP: 10.Case Discussion: Integrating PSMA PET for Focal Boost Optimization
EP: 11.Evaluating the Role of Cu-PSMA PET Imaging in Prostate Cancer
EP: 12.Key Takeaways and Future Perspectives: PSMA PET Imaging in Prostate Cancer
Video content above is prompted by the following:
- Please share an example where you implemented a focal boost based on prostate-specific membrane antigen (PSMA) uptake intensity.
- What findings did PSMA PET imaging provide, and how did this help guide your decisions?
- Briefly comment on this case and discuss implications for the practice setting.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
![A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Ff5ef402e3456a83ca4765506f26761d323734d14-446x339.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "A retrospective study shows that [177Lu]Lu-PSMA-617 retreatment led to a median OS of 14.5 months in castration-resistant prostate cancer.")
